Revalesio’s RNS60 Demonstrates Promise in First Human Asthma Trial

Revalesio Corporation will present clinical efficacy and safety data for RNS60 at the annual ACAAI meeting in Boston this week. ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5,000 members devoted to the specialty of allergy and immunology.

In this first in man asthma study, RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the Phase I study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma. These findings demonstrate that RNS60, a novel product containing charge-stabilized nanostructures (CSN), is safe and has therapeutic benefit in human subjects suffering from asthma.

These data suggest CSN solutions provide an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases. The therapeutic activity seen in Revalesio’s RNS60 is a promising alternative to steroid treatments currently used to control asthma exacerbations.

Revalesio has initiated a further clinical investigation of RNS60 in asthma in combination with the inhaled steroid budesonide. The study will evaluate RNS60 in combination with high and low dose budesonide over a 28 day period to evaluate the effect of the paired therapy on FEV1 scores and other respiratory parameters.